Clinical profiles of post‐load glucose subgroups and their association with glycaemic traits over time: An IMI‐DIRECT study
Year: 2020
Type: article
Abstract: AIM: To examine the hypothesis that, based on their glucose curves during a seven-point oral glucose tolerance test, people at elevated type 2 diabetes risk can be divided into subgroups with different clinical profiles at baseline and different degrees of subsequent glycaemic deterioration. METHODS: We included 2126 participants at elevated type 2 diabetes risk from the Diabetes Research on Patient Stratification (IMI-DIRECT) study. Latent class trajectory analysis was used to identify subgroups from a seven-point oral glucose tolerance test at baseline and follow-up. Linear models quantified the associations between the subgroups with glycaemic traits at baseline and 18 months. RESULTS: At baseline, we identified four glucose curve subgroups, labelled in order of increasing peak levels as 1-4. Participants in Subgroups 2-4, were more likely to have higher insulin resistance (homeostatic model assessment) and a lower Matsuda index, than those in Subgroup 1. Overall, participants in Subgroups 3 and 4, had higher glycaemic trait values, with the exception of the Matsuda and insulinogenic indices. At 18 months, change in homeostatic model assessment of insulin resistance was higher in Subgroup 4 (β = 0.36, 95% CI 0.13-0.58), Subgroup 3 (β = 0.30; 95% CI 0.10-0.50) and Subgroup 2 (β = 0.18; 95% CI 0.04-0.32), compared to Subgroup 1. The same was observed for C-peptide and insulin. Five subgroups were identified at follow-up, and the majority of participants remained in the same subgroup or progressed to higher peak subgroups after 18 months. CONCLUSIONS: Using data from a frequently sampled oral glucose tolerance test, glucose curve patterns associated with different clinical characteristics and different rates of subsequent glycaemic deterioration can be identified.
Source: Diabetic Medicine
DOI: 10.1111/dme.14428
Authors: M. Obura, J. W. J. Beulens, R. Slieker, A. D. M. Koopman, T. Hoekstra, G. Nijpels, P. Elders, J. M. Dekker, R. W. Koivula, A. Kurbasic, M. Laakso, T. H. Hansen, M. Ridderstråle, T. Hansen, I. Pavo, I. Forgie, B. Jablonka, H. Ruetten, A. Mari, M. I. McCarthy, M. Walker, T. J. McDonald, M. H. Perry, E. R. Pearson, P. W. Franks, L. M. ‘t Hart, F. Rutters
Institutions: Amsterdam Public Health, Amsterdam UMC Location Vrije Universiteit Amsterdam, University Medical Center Utrecht, Leiden University Medical Center, Vrije Universiteit Amsterdam, Lund University, University of Oxford, Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Eastern Finland, Kuopio University Hospital, University of Copenhagen, University of Southern Denmark, Novo Nordisk Foundation, Slagelse Hospital, Novo Nordisk Foundation Center for Basic Metabolic Research, Eli Lilly (United States), University of Dundee, Sanofi (Germany), National Research Council, Centre for Human Genetics, Newcastle University, University of Exeter, Royal Devon & Exeter NHS Foundation Trust, NIHR Exeter Clinical Research Facility, Royal Devon University Healthcare NHS Foundation Trust, Harvard University, Leiden University
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,400
OpenAlex ID: W3092748468
